<DOC>
	<DOCNO>NCT02706847</DOCNO>
	<brief_summary>The comparison safety efficacy two dose ABT-494 versus placebo participant rheumatoid arthritis stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug ( csDMARD ) .</brief_summary>
	<brief_title>A Study Compare ABT-494 Placebo Subjects With Rheumatoid Arthritis Stable Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs ( csDMARDs ) Who Have Inadequate Response Intolerance Biologic DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis ( RA ) &gt; = 3 month . Subjects treat &gt; = 3 month &gt; = 1 bDMARD therapy , continue exhibit active RA discontinue due intolerability toxicity , irrespective treatment duration prior first dose study drug . Subjects receive csDMARD therapy &gt; = 3 month stable dose &gt; = 4 week prior first dose study drug . The following csDMARDs allow : methotrexate ( MTX ) , sulfasalazine , hydroxychloroquine , chloroquine , leflunomide . A combination two background csDMARDs allow except combination MTX leflunomide . Meets follow criterion : &gt; = 6 swollen joint ( base 66 joint count ) &gt; = 6 tender joint ( base 68 joint count ) Screening Baseline Visits . Prior exposure Janus kinase ( JAK ) inhibitor ( include limit tofacitinib , baricitinib , filgotinib ) . Current diagnosis inflammatory joint disease RA . Current diagnosis secondary Sjogren 's Syndrome permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Antirheumatic agent</keyword>
	<keyword>Anti-inflammatory agent</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Arthritis</keyword>
</DOC>